Comparative Pharmacology
Head-to-head clinical analysis: JANUVIA versus JENTADUETO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUVIA versus JENTADUETO.
JANUVIA vs JENTADUETO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Jentadueto is a combination of linagliptin and metformin. Linagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP) and enhancing glucose-dependent insulin secretion while suppressing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
100 mg orally once daily
Administered orally twice daily with meals. Initial dose: one tablet JENTADUETO 5 mg/500 mg or 5 mg/1000 mg; subsequent titration based on glycemic response. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.
None Documented
None Documented
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs).
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal.
Category C
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor / Biguanide Combination